2017 Annual Report and 2018 AGM Notice

RNS Number : 2652Q

Shield Therapeutics PLC

05 June 2018

 

Shield Therapeutics plc

("Shield" or the "Company")

2017 Annual Report and 2018 AGM Notice

London, UK, 5 June 2018. Shield Therapeutics plc (LSE:STX), announces that the following documents have been sent to shareholders:

•              Annual Report and Accounts for the year ended 31 December 2017

•              Notice of Annual General Meeting ("AGM") 2018

In accordance with the AIM Rule 26, these documents are available on Company's website at, https://www.shieldtherapeutics.com/investors/corporate-documents/.

The AGM is scheduled to be held at 2.00pm BST on Wednesday 27 June 2018 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London, EC2M 7SH.

-Ends-

For further information please contact:

Shield Therapeutics plc                                                                                                       [phone]

Carl Sterritt, Chief Executive Officer

Karl Keegan, Chief Financial Officer

Nominated Advisor and Joint Broker                                                                              [phone]

Liberum Capital Limited

Christopher Britton/Steve Pearce

Joint Broker                                                                                                                          [phone]

Peel Hunt LLP

James Steel/Christopher Golden

Financial PR Advisor                                                                                                            [phone]

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

About Shield Therapeutics plc

Shield Therapeutics is a commercial stage pharmaceutical company, delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of all adults with iron deficiency with or without anaemia which has exclusive IP rights until the mid-2030's.  For more information please visit www.shieldtherapeutics.com.

 

END

 

 

MSCUGUMPQUPRPUC